Amphotericin B: CAS No: 1397-89-3 Amphotericin B is an API used to treat a number of fungal infections. This pharmaceutical ingredient is aggressive when interacting with the fungus which is why it’s generally used for serious cases only. However, it’s also proven itself to be one of the most effective ways to stop the spread[…]
Amphotericin B: A Serious and Effective Treatment for Extreme Fungal Infections
Anti-Fungal, Drug Research & Development API Tags: Amphotericin B Jul 25, 2018
Anidulafungin: An Effective Echinocandin Against Aggressive Fungal Infections
Anti-Fungal Tags: Amphotericin BAnidulafungin May 10, 2018
Anidulafungin CAS No: 166663-25-8 Anidulafungin is an antifungal API used to combat general yeast infections found in the blood, stomach, or esophagus and some varieties of Aspergillus. As an echinocandin, it inhibits the growth of fungal cell walls which results in either fungal cell instability or death. Echinocandins are unique in that they affect the[…]
Spotlight on Posaconazole: A Leading Antifungal Medication
Anti-Fungal Tags: Amphotericin BAntifungalfungusPosaconazole Mar 20, 2018
Posaconazole CAS No:171228-49-2 Posaconazole is a type of oral triazole antifungal API that has shown a high rate of efficacy for a number of fungal conditions without the risk of severe side effects. While many antifungal medications have ostensibly similar jobs, each one has their own limitations and patient disadvantages. Posaconazole was developed as an[…]
3 of the Newest API’s in the Dermatological Antifungal Segment
Anti-Fungal, EU Approved 2014, FDA Approved 2016 Tags: CrisaboroledermatitiseczemaEfinaconazolefungal infectionsPsoriasisTavaborole Jan 16, 2018
The dermatological antifungal segment has three more FDA approved options. This is good news for a specialty area that could use more diversity when it comes to treating fungal infections. Tavaborole and Efinaconazole were both approved by the FDA in 2014 to treat fungi of the nail and nailbeds, and Crisaborole was approved in 2016[…]
Posaconazole as a Reliable Antifungal Therapy
Anti-Fungal Tags: acute myeloid leukemiaHIV infection Oct 20, 2015
The use of Posaconazole, also known as the brand name Noxafil, continues to be a reliable and effectual therapy for fighting fungal infections. Posaconazole is FDA approved to treat fungal infections occurring in patients with weakened immune systems, like patients with HIV infection or those who are recovering from stem cell transplantation. In March 2014,[…]
Caspofungin Therapy Aids ALL Patients with Invasive Fungal Disease
Anti-Fungal, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: acute lymphoblastic leukemia Jun 12, 2015
Exciting news was shared in the January 2015 issue of Mycoses, with clinical data revealing that the use of Caspofungin to treat invasive fungal disease in leukemia patients was both positive and responsive. Adult patients who were diagnosed with acute lymphoblastic leukemia attained relief from their suspected fungal disease after the clinical use of Caspofungin.[…]
Luliconazole a Gold Standard Treatment for Fungal Infections
Anti-Fungal, Drug Research & Development API May 22, 2015
Known as the brand name azole antifungal cream Luzu, which is marketed by Valeant Pharmaceuticals, Luliconazole 1% cream remains a gold standard treatment for a variety of fungal infections. Luliconazole is approved by the FDA to treat the following: interdigital tinea pedis, or athlete’s foot tinea corporis, also known as ringworm tinea cruris, coined jock[…]
Micafungin Remains a Viable Treatment for Candida Infections
Anti-Fungal, Drug Research & Development API, FDA Approved 2013 Tags: United States Apr 08, 2015
As the fourth most common cause of hospital-acquired bloodstream infections in the United States, Invasive Candidiasis is a concern for any patient battling a fungal infection. Micafungin, also known as the brand name Mycamine, which is marketed by Astellas, is an effective antifungal agent. By inhibiting the synthesis of 1,3-beta-D-glucan, Micafungin proves to be a[…]
Tavaborole Approved as Antifungal Toenail Treatment
Anti-Fungal, Drug Research & Development API, FDA Approved 2014 Oct 20, 2014
Anacor Pharmaceuticals, Inc. ANAC, announced on Jul 08, 2014 that the FDA has approved the New Drug Application for Tavaborole, which is marketed as KERYDIN™ topical solution, 5%. Tavaborole was designed to be convenient for patients to use and it’s the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. Onychomycosis[…]
More Than Three-Quarters of U.S. Women Will Benefit From Butoconazole Nitrate
Anti-Fungal, Drug Research & Development API, Patent Expiration 2017 Feb 12, 2013
Butoconazole Nitrate, CAS number 64872-77-1 is also known as the brand name GYNAZOLE-1. Marketed by Ther-Rx Corporation, the patent for this vaginal cream expires November 17, 2017. Indicated for the treatment of vulvovaginal candidiasis, or infections caused by Candida, butoconazole is available in a 2% strength cream. Statistically Candida, or yeast infections, are extremely common.[…]
- 1
- 2
